Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of carnosic acid in preparing ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and medicine for treating osteoporosis

A technology of carnosic acid and osteoporosis, applied in the field of medicine

Inactive Publication Date: 2018-05-15
CHINA PHARM UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above-mentioned effects of carnosic acid have not yet been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of carnosic acid in preparing ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and medicine for treating osteoporosis
  • Application of carnosic acid in preparing ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and medicine for treating osteoporosis
  • Application of carnosic acid in preparing ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and medicine for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Inhibitory effect of carnosic acid on ERRα expression in cells

[0028] 1. Experimental materials

[0029] RAW264.7 cells: from ATCC;

[0030]MEMα medium (Gibco, U.S.); fetal bovine serum (Gibco, U.S.); trypsin (Gibco, U.S.); penicillin-streptomycin mixture (Gibco, U.S.); non-essential amino acid glutamine (Gibco, U.S.); Phosphatase inhibitors (Roche, Switzerland); protease inhibitors (Roche, Switzerland); SDS-PAGE protein loading buffer (5x) (Shanghai Beyond Biotechnology Co., Ltd.); 30% polyacrylamide (Shanghai Beyond Bio Technology Co., Ltd.); 1.5MTris-HCl (pH 8.8) (Shanghai Biyuntian Biotechnology Co., Ltd.); 10% sodium dodecyl sulfonate (SDS) (Shanghai Beyontien Biotechnology Co., Ltd.); ammonium persulfate (APS ) (Biosharp Biotechnology Co., Ltd.); Tetramethylethylenediamine (TEMED) (Amresco, the United States); 0.5M Tris-HCl (pH6.8) (Shanghai Biyuntian Biotechnology Co., Ltd.); Tris (Nanjing Shengxing Biological Technology Co., Ltd.); Technology Co....

Embodiment 2

[0057] Example 2: Inhibitory effect of carnosic acid on osteoporosis in ovariectomized mice

[0058] 1. Experimental materials

[0059] Mice were purchased from the Institute of Model Animals, Nanjing University;

[0060] Main reagents and kits: Sodium hydroxymethylcellulose (Sinopharm Chemical Reagent Co., Ltd.); PBS buffer (Jiangsu Kaiji Biotechnology Co., Ltd.); shavings bedding (Jiangsu Synergy Bioengineering Co., Ltd.); Feed (Jiangsu Synergy Shengsu Engineering Co., Ltd.); alkaline phosphatase (ALP) detection kit (Wuhan Huamei Bioengineering Co., Ltd.); calcium (Ca) detection kit (Nanjing Jiancheng Bioengineering Institute); inorganic phosphorus ( P) Detection kit (Nanjing Jiancheng Bioengineering Institute); mouse serum type 1 collagen C-terminal peptide (CTX-1) ELISAKit (Wuhan Huamei Bioengineering Co., Ltd.); mouse serum anti-tartrate acid phosphatase (strACP) detection Kit (Nanjing Jiancheng Bioengineering Institute); 4% neutral paraformaldehyde (Jiangsu Kaiji Biote...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of carnosic acid in preparing an ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and a medicine for treating osteoporosis. Through in-vitro experiments, the inventor finds that carnosic acid is an effective ERRalpha expression inhibitor and is capable of inhibiting expression of related osteoporosis markers in osteoporosis cell models; in-vivo experiments show that due to adoption of the carnosic acid, physiological phenomena (such as tibia BV / TV reduction, tibia Tb.Th reduction, tibia Tb.N reduction, tibia Tb.SP increase and tibia SM1 increase) caused by mouse ovary excision are reversed to a certain extent, then bone defects (such as bone substance reduction and / or microstructure degradation of bone) caused by estrogen deficiency symptoms can be treated, and the carnosic acid has the prospect of being developed into medicines for treating osteoporosis caused by menopause.

Description

technical field [0001] The invention belongs to the field of medicine and relates to the new application of known compounds, in particular to the application of carnosic acid for preparing ERRα expression inhibitors and medicines for treating osteoporosis. Background technique [0002] Osteoporosis (Osteoporosis, OP) is a systemic metabolic bone disease characterized by decreased bone mass, degenerative changes in bone tissue fibrous structure, increased bone fragility, and prone to fractures. Reduced and prone to fractures. With the advent of an aging society, the incidence of osteoporosis is also increasing. After menopause, the estrogen level in the body of women is significantly reduced, and bone loss is accelerated, resulting in a faster rate of bone resorption than bone formation, which eventually leads to postmenopausal bone loss. Postmenopausal osteoprosis (PMOP) has become a common disease in postmenopausal women. [0003] ERR is divided into three subtypes: α, β,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61P19/10
CPCA61K31/192
Inventor 徐晓军李萍周亚萍
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com